GLP-1/GCG Dual Agonist LIGHT-COG (NCT07083154)

Overview

flowchart TD
    clinical_trials_nct07083154["GLP-1/GCG Dual Agonist LIGHT-COG NCT07083154"]
    style clinical_trials_nct07083154 fill:#4fc3f7,stroke:#333,color:#000
    clinical_trials_nct0_0["Trial Information"]
    clinical_trials_nct07083154 -->|"includes"| clinical_trials_nct0_0
    style clinical_trials_nct0_0 fill:#81c784,stroke:#333,color:#000
    clinical_trials_nct0_1["Study Design"]
    clinical_trials_nct07083154 -->|"includes"| clinical_trials_nct0_1
    style clinical_trials_nct0_1 fill:#ef5350,stroke:#333,color:#000
    clinical_trials_nct0_2["Arms"]
    clinical_trials_nct07083154 -->|"includes"| clinical_trials_nct0_2
    style clinical_trials_nct0_2 fill:#ffd54f,stroke:#333,color:#000
    clinical_trials_nct0_3["Primary Endpoint"]
    clinical_trials_nct07083154 -->|"includes"| clinical_trials_nct0_3
    style clinical_trials_nct0_3 fill:#ce93d8,stroke:#333,color:#000
    clinical_trials_nct0_4["Secondary Endpoints"]
    clinical_trials_nct07083154 -->|"includes"| clinical_trials_nct0_4
    style clinical_trials_nct0_4 fill:#4fc3f7,stroke:#333,color:#000
    clinical_trials_nct0_5["Eligibility Criteria"]
    clinical_trials_nct07083154 -->|"includes"| clinical_trials_nct0_5
    style clinical_trials_nct0_5 fill:#81c784,stroke:#333,color:#000

The LIGHT-COG Study (NCT07083154) is a Phase 3 clinical trial investigating the efficacy, safety, and tolerability of a GLP-1/GCG (Glucagon) Dual Receptor Agonist in patients with Type 2 Diabetes and early dementia, particularly Alzheimer’s disease

This trial represents a novel therapeutic approach targeting the metabolic dysfunction hypothesis of neurodegeneration, leveraging the neuroprotective effects of GLP-1 receptor agonism. It is one of the first large-scale Phase 3 trials to directly test whether metabolic modulation can slow cognitive decline in AD patients with diabetes.

Trial Information

Study Design

Arms

Primary Endpoint

• Change in iADRS (Integrated Alzheimer’s Disease Rating Scale) score from baseline to Week 52

• The iADRS combines cognitive testing (ADAS-Cog) with functional assessment (ADCS-ADL)

Secondary Endpoints

Eligibility Criteria

Inclusion Criteria

1. Age 55-85 years

2. Diagnosis of mild cognitive impairment (MCI) due to AD or mild dementia due to AD (NIA-AA criteria)

3. Confirmed Type 2 Diabetes (HbA1c 6.5-8.5%)

4. MMSE score 20-28

5. Stable diabetes medication for ≥8 weeks prior to screening

6. Have a reliable caregiver/informant

Exclusion Criteria

1. Diagnosis of non-AD dementia

2. History of Type 1 diabetes or diabetic ketoacidosis

3. Severe cardiovascular disease (NYHA Class III-IV, recent MI)

4. History of pancreatitis

5. Active cancer or cancer within 5 years

6. MRI evidence of significant vascular disease

Scientific Rationale

Type 2 Diabetes and Alzheimer’s Disease Link

Epidemiological studies have established a strong link between Type 2 Diabetes and increased risk of Alzheimer’s disease. The metabolic dysfunction in diabetes contributes to^{2Type 3 diabetes: a link between Alzheimer's disease and diabetes2021 · CNS Drugs · DOI 10.1007/s40263-021-00830-5Open reference}:

1. Impaired glucose metabolism in the brain

   • Brain insulin resistance reduces glucose utilization

   • Neuronal energy crisis contributes to dysfunction

   • Impaired insulin signaling affects synaptic plasticity

2. Increased neuroinflammation

   • Chronic low-grade inflammation in diabetes

   • Activated microglia produce pro-inflammatory cytokines

   • Neuroinflammation accelerates tau pathology

3. Oxidative stress

   • Mitochondrial dysfunction from chronic hyperglycemia

   • Advanced glycation end-products (AGEs) accumulate

   • Antioxidant systems become overwhelmed

4. Blood-brain barrier dysfunction

   • Diabetes impairs endothelial function

   • Reduced clearance of Aβ from brain

   • Increased leakiness allows peripheral toxins into CNS

The “Type 3 Diabetes” Hypothesis

Emerging evidence supports the concept of Alzheimer’s disease as a form of diabetes^{2Type 3 diabetes: a link between Alzheimer's disease and diabetes2021 · CNS Drugs · DOI 10.1007/s40263-021-00830-5Open reference}:

• Brain insulin resistance: AD brains show reduced insulin receptor expression and signaling

• Impaired glucose uptake: FDG-PET shows hypometabolism in AD-affected regions

• Aβ effects on insulin signaling: Aβ oligomers interfere with insulin receptor function

• Tau effects on glucose metabolism: Tau pathology disrupts insulin signaling

GLP-1 Receptor Agonists as Neuroprotective Agents

GLP-1 receptor agonists, originally developed for diabetes treatment, have shown neuroprotective properties in preclinical models^{3GLP-1 receptor agonists for neuroprotection in Alzheimer's disease2023 · Nature Reviews Neurology · DOI 10.1038/s41582-023-00765-6Open reference}:

Why Dual GLP-1/GCG Agonism?

The dual GLP-1/GCG agonist may provide enhanced neuroprotection:

GLP-1 Receptor Effects

• Enhances insulin sensitivity in the brain

• Reduces neuroinflammation

• Promotes synaptic plasticity and neurogenesis

• Decreases amyloid-beta toxicity

GCG Receptor Effects

• Regulates glucose metabolism

• Modulates hepatic glucose output

• May improve cerebral energy metabolism

• Enhances lipolysis and energy expenditure

The dual mechanism addresses both peripheral and central metabolic dysfunction, which are increasingly recognized as key contributors to Alzheimer’s disease pathogenesis^{4Metabolic dysfunction in Alzheimer's disease2022 · Nature Reviews Disease Primers · DOI 10.1038/s41582-022-00699-0Open reference}.

Clinical Sites

Participating Institutions (China)

Biomarker Program

Target Engagement

Disease Progression Markers

Imaging

• MRI: Hippocampal atrophy rate

• FDG-PET: Cerebral glucose metabolism

• Amyloid PET: (subset) Amyloid plaque burden

Competitive Landscape

GLP-1 Agonists in Alzheimer’s Disease

Metabolic Therapies in Development

Why This Trial Matters

1. Addressing the Comorbidity

• ~30% of AD patients have Type 2 Diabetes

• Diabetes accelerates cognitive decline

• No approved therapies addressing this comorbidity

2. Disease-Modifying Potential

• Targets underlying metabolic dysfunction rather than just symptoms

• Addresses both peripheral and central pathology

• May slow progression rather than merely symptomatic benefit

3. Large Phase 3 Trial

• 420 participants provides robust efficacy data

• 52-week duration adequate for detecting clinical benefit

• Comprehensive biomarker program to understand mechanism

4. Unmet Medical Need

• No approved therapies for Alzheimer’s that target metabolic pathways

• Current AD treatments (cholinesterase inhibitors, memantine) provide limited benefit

• Metabolic approaches offer a novel mechanism of action

5. Potential for Precision Medicine

• May identify responders based on metabolic status

• Biomarker program will inform personalized treatment approaches

• Could lead to combination therapies for diabetes-AD patients

Safety Considerations

Expected Adverse Events

Monitoring Plan

• Regular blood glucose monitoring

• Adverse event assessment at each visit

• Pancreatic enzyme monitoring (amylase, lipase)

• Cardiovascular monitoring (ECG, vital signs)

Regulatory Considerations

China NMPA Context

• This trial is conducted under China NMPA regulations

• Results may support approval in China

• International multi-regional trials may follow

Potential for Global Development

• Success could lead to global Phase 3 program

• GLP-1 agonists have established safety profiles

• May pursue FDA/EMA approval for AD indication

Current Status (March 2026)

The LIGHT-COG trial is actively recruiting as of March 2026. Enrollment is expected to complete by mid-2027, with topline results in 2029.

Milestones:

• September 2025: First patient enrolled

• December 2025: 50 patients enrolled

• Target: 420 patients by mid-2027

Clinical Significance

This trial is significant because:

1. First large-scale Phase 3 testing metabolic therapy in AD with diabetes

2. Novel mechanism targeting brain insulin resistance

3. Addresses comorbidity affecting millions of AD patients

4. May establish new treatment paradigm for AD

5. Biomarker-rich design will elucidate mechanism

If Positive

• Would support “Type 3 diabetes” hypothesis

• Could lead to GLP-1 agonist approval for AD

• Would validate metabolic approach more broadly

• May expand to non-diabetic AD patients

If Negative

• Would not necessarily refute metabolic hypothesis

• Could indicate wrong target or inadequate dosing

• May inform combination therapy approaches

• Would guide future trial designs

Cross-References

• Alzheimer’s Disease — Disease overview

• Type 3 Diabetes Hypothesis — Mechanism

• GLP-1 and Neuroprotection — Drug class

• Metabolic Syndrome and Alzheimer’s Disease — Mechanism

• Diabetes and Dementia Risk — Comorbidity